Tomorrowland’s Forecast: The Rocky Start to At-Home Genetics Testing: VIDEO


The FDA's primary concern with 23andMe is that people who buy their kit could act on the company's data analysis by undergoing drastic and/or unnecessary procedures – like MRIs or even mastectomies if a false positive is given for the person's risk of breast cancer. On the other side of the issue, the FDA also worries that people using the results from the kit may get a false sense of complacency towards certain health risks. They worry that people may not be fully aware that these tests, at least in their present form, are meant to supplement medical services, not replace them. And with the rules, regulations, and interpretations of at-home genetics testing still so nascent, the FDA's concerns do indeed seem warranted.

The controversy over whether and how the FDA should (or can) regulate genetic tests has been around long before 23andMe. But the FDA's recent actions, and 23andMe's response, will have much larger ramifications for the field of genetic testing. Because 23andMe is the only major player in the "direct to consumer" genomic testing industry, insiders see the company's response in the coming months as having the potential to set a precedent for the future of the field. In an interview with Venturebeat last week, 23andMe spokeswoman Catherine Afarian agreed, saying that the company's decision will likely shape the entire genetics industry, which she believes is the "future of medicine."

"Our mission is unchanged," said Afarian. "We are not going anywhere, although we recognize that the FDA process will take time." 23andMe founder and chief executive Anne Wojcicki recently echoed this sentiment in a blog post, where she claimed to "stand behind the data."

23andMe kitIndeed, there's no denying the positive benefits that the data from these kits can provide. Before the FDA's decision to put a stop to 23andMe's genetic analysis, a good friend of mine purchased and submitted a test kit. He grew up in foster care and, as a result, didn't have a detailed family medical history record like many of us. With 23andMe's results though, he was able to find out valuable information about certain inherited health risks and traits. For example, he found out that he's at decreased risk for developing male pattern baldness later in life. He also discovered that he's a carrier for the hereditary hemochromatosis mutation (iron overload), which could potentially be passed to his offspring in the future.

But he also agreed that the test can be misleading. For example, he says, just because the test showed that he is partially resistant to HIV does not give him (or anyone else with those results) the right to throw caution to the wind and engage in unsafe sex. Like the FDA, he thinks people need to be smart about their results and should rely primarily on information provided by physicians and medical experts.

Regardless, the coming weeks and months will be crucial for the long-term future of 23andMe and the genetics industry as a whole. For now though, we'll just have to wait and see.

But what about you? Do you think the FDA has doomed the at-home genetics testing field? Or perhaps this setback is just part of the long process of turning 23andMe into the only FDA-approved direct-to-consumer genetic company? Sound off in the comments section below. 

News tips? Comments/Suggestions? Tweet me @kylergee